Theraflu-d Flu Relief Max Strength Plus Nasal Decongestant Syrup
NDC Package 0067-0115-01
Package Information
Theraflu-d Flu Relief Max Strength Plus Nasal Decongestant (acetaminophen, dextromethorphan hbr, pseudoephedrine hcl) syrups is do not use more than directedmeasure the dose correctly using the enclosed dosing cupadults and children 12 years of age and over: take every 6 hours in dosing cup provided, while symptoms persistdo not take more than 3 doses (90 mL) in 24 hours unless directed by a doctorchildren under 12 years of age: do not useAgeDoseadults and children 12 years of age and over30 mL every 6 hourschildren under 12 years of agedo not use. This formulation utilizes a syrup delivery system. Marketed by Haleon Us Holdings Llc, this product is identified by NDC 0067-0115 and is authorized under FDA application M012.
Identification & Billing
- RxCUI: 1369927 - acetaminophen 1000 MG / dextromethorphan HBr 30 MG / pseudoephedrine HCl 60 MG in 30 mL Oral Solution
- RxCUI: 1369927 - acetaminophen 33.3 MG/ML / dextromethorphan hydrobromide 1 MG/ML / pseudoephedrine hydrochloride 2 MG/ML Oral Solution
- RxCUI: 1369927 - acetaminophen 1000 MG / dextromethorphan hydrobromide 30 MG / pseudoephedrine hydrochloride 60 MG per 30 ML Oral Solution
- RxCUI: 1369927 - APAP 1000 MG / dextromethorphan hydrobromide 30 MG / pseudoephedrine hydrochloride 60 MG per 30 ML Oral Solution
- RxCUI: 1369927 - APAP 33.3 MG/ML / Dextromethorphan Hydrobromide 1 MG/ML / Pseudoephedrine Hydrochloride 2 MG/ML Oral Solution
Clinical Specifications
- Adrenergic alpha-Agonists - [MoA] (Mechanism of Action)
- Sigma-1 Agonist - [EPC] (Established Pharmacologic Class)
- Sigma-1 Receptor Agonists - [MoA] (Mechanism of Action)
- Uncompetitive N-methyl-D-aspartate Receptor Antagonist - [EPC] (Established Pharmacologic Class)
- Uncompetitive NMDA Receptor Antagonists - [MoA] (Mechanism of Action)
- alpha-Adrenergic Agonist - [EPC] (Established Pharmacologic Class)
Regulatory & Marketing
Hierarchy Structure
- 0067 - Haleon Us Holdings Llc
- 0067-0115 - Theraflu-d Flu Relief Max Strength Plus Nasal Decongestant
- 0067-0115-01 - 1 BOTTLE in 1 CARTON / 237 mL in 1 BOTTLE
- 0067-0115 - Theraflu-d Flu Relief Max Strength Plus Nasal Decongestant
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 0067-0115-01 identifies a specific commercial package of 1 bottle in 1 carton / 237 ml in 1 bottle of Theraflu-d Flu Relief Max Strength Plus Nasal Decongestant, a human over the counter drug labeled by Haleon Us Holdings Llc. This syrup is formulated for oral use and contains acetaminophen; dextromethorphan hydrobromide; pseudoephedrine hydrochloride as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Haleon Us Holdings Llc on June 19, 2024. The current certification is valid through December 31, 2026.
How is this Haleon Us Holdings Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 00067011501. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.